Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Biotronik
HQ Germany · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
May 2026: investigative outlet Investico alleged Biotronik ignored reports for years of problems with its defibrillator leads causing erroneous shocks; Biotronik firmly denies any wrongdoing and says nothing is wrong with its product.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Biotronik found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Jan 2025: Germany's BfArM published a Biotronik field safety notice for its Pulsar-35 implant. May 2026 media reports alleged defibrillator lead problems (denied by Biotronik); HSH found no related regulator action.
Contract performance
No notable go-lives, troubled implementations, terminations or customer disputes involving Biotronik found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.